MICHAEL BYRD: Open Payments
NPI 1255094678 · MILLEDGEVILLE, GA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,316 in 41 payments from 9 companies in 2025. Trend: 2023 $517 · 2024 $648 · 2025 $1,316
Food & beverage: $1,310Education: $5
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 10 | $416 |
| E.R. Squibb & Sons, L.L.C. | 5 | $236 |
| Janssen Pharmaceuticals, Inc | 7 | $192 |
| Teva Pharmaceuticals USA, Inc. | 7 | $184 |
| Supernus Pharmaceuticals, Inc. | 4 | $95 |
| Otsuka America Pharmaceutical, Inc. | 3 | $77 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $56 |
| Alkermes, Inc. | 1 | $31 |
| Lundbeck LLC | 1 | $27 |
Products named: INGREZZA, COBENFY, INVEGA SUSTENNA, UZEDY, Qelbree, CAPLYTA, ABILIFY MAINTENA, AUSTEDO XR.
Industry payments across GA — which companies pay providers there.
